Medical Condition News

RSS

FDA approves two drugs for long-term weight loss

Options are limited in America's battle of the bulge. While diet and exercise can help in the short term, they are frustratingly ineffective in the long run.

12 Feb 2014

New imaging technique can predict common congenital heart abnormality

A new imaging technique for measuring blood flow in the heart and vessels can diagnose a common congenital heart abnormality, bicuspid aortic valve, and may lead to better prediction of complications.

12 Feb 2014

Researchers discover that bladder cancer shares genetic similarities with two forms of breast cancer

Researchers at the UNC School of Medicine conducted a comprehensive genetic analysis of invasive bladder cancer tumors to discover that the disease shares genetic similarities with two forms of breast cancer.

12 Feb 2014

Researchers demonstrate new approach to treating muscular dystrophy

Researchers at Washington University School of Medicine in St. Louis have demonstrated a new approach to treating muscular dystrophy. Mice with a form of this muscle-weakening disease showed improved strength and heart function when treated with nanoparticles loaded with rapamycin, an immunosuppressive drug recently found to improve recycling of cellular waste.

12 Feb 2014

EMT program in human cells may provide an effective approach for treating triple-negative breast cancer

A new study led by University of Kentucky Markey Cancer Center researcher Peter Zhou shows that targeting Twist, a nuclear protein that is an accelerant of the epithelial-mesenchymal transition (EMT) program in human cells, may provide an effective approach for treating triple-negative breast cancer.

12 Feb 2014

Red wine and dark chocolate taste great and have heart-healthy components

Forget the oysters and the champagne this Valentine's Day. If you want to keep your true love's heart beating strong, the real foods of love are dark chocolate and red wine, said Loyola University Health System preventive heart specialist Sara Sirna, MD.

12 Feb 2014

IMF announces approval of POMALYST medication in Canada for patients with myeloma

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - said POMALYST (pomalidomide) approval by Health Canada provides patients the most up-to-date oral therapy available for patients who have exhausted all other treatments.

11 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Surgeons now use minimally invasive robotic surgical system for Whipple procedure

The Whipple procedure, used to remove tumors from pancreatic cancer patients, is one of surgery's most extensive and challenging operations.

11 Feb 2014

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.

11 Feb 2014

St. Joseph's Hospital opens new $20 million Heart Institute

St. Joseph's Hospital entered the next era of cardiac care by opening a new $20 million Heart Institute on Feb. 10, 2014. St. Joseph's Hospital Heart Institute is one of the most advanced and comprehensive centers for cardiovascular medicine in Florida, performing more than 50,000 adult cardiac catheterizations. It is also has the only pediatric catheterization program in Hillsborough County.

11 Feb 2014

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients.

11 Feb 2014

AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

The AstraZeneca HealthCare Foundation's Connections for Cardiovascular Health program today announced it will award nearly $3.7 million in grants to 19 nonprofit organizations dedicated to improving cardiovascular health in local communities.

11 Feb 2014

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

11 Feb 2014

Eternity Healthcare developing saliva-based noninvasive sugar monitoring device

Eternity Healthcare Inc., a medical device and diagnostic company specializing in diabetes management, announced today that they are in development of a noninvasive sugar monitoring device using saliva instead of blood. The technology utilizes an ultra sensitive sugar monitor and an additional sensor for salivary amylase enzyme activity.

From Medtronic 11 Feb 2014

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Cardiome Pharma Corp. today announced that its subsidiary, Correvio GmbH, has entered into an agreement with Tamro AB, headquartered in Gothenburg, Sweden, to distribute BRINAVESS (vernakalant IV) to customers in the Swedish market.

11 Feb 2014

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).

11 Feb 2014

Concussions account for 5.8% to 8.6% of injuries in soccer games

Soccer is the most-popular and fastest-growing sport in the world and, like many contact sports, players are at risk of suffering concussions from collisions on the field.

11 Feb 2014

Study: Urgency incontinence is the most troubling urinary symptom in men and women

Urgency incontinence is considered the most troubling urinary symptom in both men and women, according to a recent study published in the leading urology journal, European Urology.

11 Feb 2014

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia (AML), to promote progression of the disease.

11 Feb 2014

Medical Condition News

FDA approves two drugs for long-term weight loss

New imaging technique can predict common congenital heart abnormality

Researchers discover that bladder cancer shares genetic similarities with two forms of breast cancer

Researchers demonstrate new approach to treating muscular dystrophy

EMT program in human cells may provide an effective approach for treating triple-negative breast cancer

Red wine and dark chocolate taste great and have heart-healthy components

IMF announces approval of POMALYST medication in Canada for patients with myeloma

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Surgeons now use minimally invasive robotic surgical system for Whipple procedure

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

St. Joseph's Hospital opens new $20 million Heart Institute

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

AstraZeneca HealthCare Foundation to award grants to 19 organizations to improve cardiovascular health

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Eternity Healthcare developing saliva-based noninvasive sugar monitoring device

Cardiome Pharma's subsidiary signs agreement with Tamro to distribute BRINAVESS in Sweden

Omeros announces additional positive data from OMS824 Phase 1 program

Concussions account for 5.8% to 8.6% of injuries in soccer games

Study: Urgency incontinence is the most troubling urinary symptom in men and women

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News